Skip to content
How cbdMD earned WSJ coverage on FDA’s CBD regulation deferral episode artwork

Mar 17, 2023 44 min

How cbdMD earned WSJ coverage on FDA’s CBD regulation deferral

from Move the Stairs: Brand Protection PR™ Hosted by mandccomms

The FDA's decision (or indecision) to punt CBD regulation to Congress continues to send shockwaves through the cannabis industry. Reputable companies, like cbdMD, say this decision will continue to encourage bad-faith actors in the CBD space, harming every company striving for industry transparency. cbdMD's Chief Science Officer & Vice-President of Regulatory Affairs, Dr. Sibyl Swift, and General Counsel, Lance Blundell join the Move the Stairs™ podcast to discuss how the development is forcing change in its overall strategy to educate consumers and journalists while maintaining brand resiliency.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

How cbdMD earned WSJ coverage on FDA’s CBD regulation deferral

0:00 44:50

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Move the Stairs: Brand Protection PR™?

This episode is 44 minutes long.

When was this Move the Stairs: Brand Protection PR™ episode published?

This episode was published on March 17, 2023.

Can I download this Move the Stairs: Brand Protection PR™ episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.